Early Risk Identification at Core of Innovative Kidney Care Partnership Between Renalytix, DaVita
January 05 2021 - 5:00AM
Kidney care innovators Renalytix AI (NASDAQ:RNLX, LSE:RENX) and
DaVita (NYSE: DVA) are partnering on a program aimed at slowing
disease progression and improving health outcomes for the nation’s
estimated 37 million adults with chronic kidney disease (CKD). The
program is expected to improve patient outcomes and provide
meaningful cost reductions for health care providers and payors by
enabling earlier intervention for patients with early-stage kidney
disease (stages 1, 2 and 3) through actionable risk assessments and
end-to-end care management.
The collaboration is expected to launch in three major markets
this year. As the program expands, DaVita and RenalytixAI intend to
pursue risk-sharing arrangements with health care providers and
payors to drive kidney disease patient care innovation, cost
efficiencies and improve quality of life.
“Almost 50% of people whose kidneys fail find out after it is
too late, and we are on a mission to change that,” said Javier
Rodriguez, Chief Executive Officer for DaVita. “Our partnership
with RenalytixAI could allow us to help slow disease progression
for the millions of people living with kidney disease.”
“This is the first clinical-grade program that delivers advanced
early-stage prognosis and risk stratification, combined with
actionable care management right to the primary care level where
the majority of kidney disease patients are being seen,” said James
McCullough, Renalytix AI Chief Executive Officer. “Making
fundamental change in kidney disease health economics and outcomes
must begin with providing a clear, actionable understanding of
disease progression risk.”
The program utilizes the KidneyIntelX in vitro diagnostic
platform from RenalytixAI, which uses a machine learning algorithm
to assess a combination of biomarkers from a simple blood draw with
features from the electronic health record to generate a
patient-specific risk score. The initial version of the
KidneyIntelX risk score identifies Type 2 diabetic patients with
early-stage CKD as low-, intermediate- or high-risk for progressive
decline in kidney function or kidney failure. The integrated
program may also help reduce kidney disease misclassification,
which leaves some higher-risk patients without recommended
treatment. The expected outcome of the collaboration will also be
used to expand indicated use claims for KidneyIntelX.
After risk stratification, program patients identified as
intermediate- and high-risk will receive care management support
through DaVita’s integrated kidney care program, for which
Renalytix will compensate DaVita in lieu of providing those
services itself. DaVita’s integrated kidney care program is
comprised of a coordinated care team, practical digital health
tools, award-winning patient education and other offerings. Focused
on the patient experience, these services are designed to empower
patients to be active in their care, delay disease progression,
improve outcomes and lower costs. DaVita’s team also closely
collaborates with the treating nephrologist, who leads the care
team, to create a seamless care experience.
For patients whose kidney disease does progress, earlier
intervention can provide the patient and treating nephrologist more
time to make an informed decision about the treatment option that
is best for them, including pre-emptive transplantation, home
dialysis or in-center dialysis. For those patients who choose to
begin dialysis, the extra time increases their chance for an
out-patient dialysis starts, which can help them to avoid starting
dialysis with a costly hospitalization.
Forward-Looking StatementsCertain statements in this press
release are forward-looking statements that are subject to risks
and uncertainties. These forward-looking statements include, for
example, statements related to the potential benefits of the
partnership between RenalytixAI and DaVita to patients, health care
providers and payors. Forward-looking statements in this press
release are based on management's current expectations. Various
important factors could cause actual results to differ materially
from these forward-looking statements, including the risks
identified in the U.S. Securities and Exchange Commission filings
of DaVita and RenalytixAI. Each of RenalytixAI and DaVita disclaims
any obligation to update any forward-looking statement contained in
this press release, except as may be otherwise required by law.
About RenalytixAIRenalytixAI
(NASDAQ:RNLX) is a developer of artificial intelligence-enabled
clinical in vitro diagnostic solutions for kidney disease, one of
the most common and costly chronic medical conditions globally. The
Company’s lead product is KidneyIntelX.com (visit
www.kidneyintelx.com) which is being designed to help make
significant improvements in kidney disease prognosis, transplant
management, clinical care, patient stratification for drug clinical
trials, and drug target discovery. For more information, visit
www.renalytixai.com.
About DaVitaDaVita (NYSE: DVA) is a health care
provider focused on transforming care delivery to improve quality
of life for patients globally. The company is one of the largest
providers of kidney care services in the U.S. and has been a leader
in clinical quality and innovation for more than 20 years. Through
DaVita Kidney Care, the company treats patients with chronic kidney
failure and end stage kidney disease. DaVita is committed to bold,
patient-centric care models, implementing the latest technologies
and moving toward integrated care offerings for all. Through these
efforts, DaVita has also become the largest provider of home
dialysis in the country. As of September 30, 2020, DaVita
served 205,300 patients at 2,809 outpatient dialysis centers
in the United States. The company also operated 291 outpatient
dialysis centers in nine countries worldwide. DaVita has reduced
hospitalizations, improved mortality, and worked collaboratively to
propel the kidney care industry to adopt an equitable and
high-quality standard of care for all patients, everywhere. To
learn more, visit DaVita.com/About.
Media Contacts:
United States:Jennifer MoritzZer0 to 5ive for RenalytixAI(917)
748-4006jmoritz@0to5.com
Outside of the United States:Walbrook PR LimitedPaul
McManus / Lianne CawthorneTel: 020 7933 8780
or renalytix@walbrookpr.comMob: 07980 541 893 / 07584 391
303
DaVita (NYSE:DVA)
Historical Stock Chart
From Sep 2024 to Oct 2024
DaVita (NYSE:DVA)
Historical Stock Chart
From Oct 2023 to Oct 2024